TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum Plasma Concentration (Cmax) for Unconjugated Naloxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-Life (t1/2) of Unconjugated Naloxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post endoscopic mucosal resection bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Total Score Change in MADRS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Edema/redness/drainage and/or severity of pain at incision site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of chills and reported fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bubble Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants with Drug-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of requesting pharmaceutical interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to First Documented Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Brock grade ≥ 1 hearing loss
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with HIV RNA levels < LOQ (400 c/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Remission defined by Crohns disease activity index (CDAI)<150
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global Cognitive Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Instrumental Activities of Daily Living (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Recurrence of Major Depression
Endpoint domain: Adverse events/effects
Primary endpoint: Sieving coefficient for peramivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of opioid-related chemical coping
Endpoint domain: Adverse events/effects
Primary endpoint: Ventilator weaning rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum size of the primary lesion complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Metabolic toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of colonoscopy preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fractional Flow Reserve at Maximal Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Change in Nail Psoriasis Severity Index (NAPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Uncorrected Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Brain activity related to set shifting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain activity related to global vs. local processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain activity related to reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hospital readmissions at six months
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pulpal Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days Step Goal Completed
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tumour to Background Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Persistence of stimulation-related changes in brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Use of Analgesics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in serum sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to failure of strategy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clocktime when child has had no fever for minimal 48h (< 37,5°C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitemy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vasculature of the nasopharyngeal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: One Year Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Radial artery measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infection after radiofrequency ablation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Stimulated C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of attention functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of memory functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Child anthropometry (height, weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain time-activity curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enzyme occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binding potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peer Engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Default Mode Network (DMN) functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: correlations between genetic polymorphisms and clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pedicular effraction grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor fluctuations of the Off time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Changes in total cerebral white matter lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: COVID-19 incidence
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients successfully completing the intervention program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of patients with normalized systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mean Change in IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Study Drug Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in scores on the Hypoglycemia Fear Survey
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Responders at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mortality until discharge
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Endocarditis of the replaced/reconstructed valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Re perfusion following Ozurdex use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of patients identifying the most important catheter criterion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analog Scale (VAS) Leg Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % change in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment-related changes in functional magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Treatment-related changes in white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart rate score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiration rate score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygen saturation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of plasma anti-AChR Abs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysautonomic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of CDAI Responders at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate variability at the stressful event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin conductance changes at the stressful event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction times at the stressful event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Muscle Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the amount of Rotation of knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of the amount of Translation of knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in the Monthly Mean Dysmenorrhea Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Monthly Mean Cumulative Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Monthly Mean Dyspareunia Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observable Difference Between Virtual Versus Actual Fluorescein Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fibrinolysis activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Psychotic relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Fasting Plasma glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biomarkers comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stress response comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intensity of thirst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lip hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dryness of the mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste in the oral cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prevalence of acute disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Plasma Concentration (Cmin) of Simeprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Simeprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Simeprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence/presence of visible cervicovaginal inflammation/irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: histological lesions of humoral rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immunodominant donor specific antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time-to-CRPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHDRS-IV-Parent:Inv Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School Grade Average (SGA)
Endpoint domain: Life impact
Endpoint subdomain: Academic functioning
Primary endpoint: Proportion of patients transported with spinal immobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients feeling comfortable
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum concentrations of tobramycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in MR flow measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post surgery inotrope score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent changes in infarction volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) or maximum feasible dose (MFD) of RGI-2001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The change of hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of myocardial infarct size to area at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cytologic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-specific IFN-γ-ELISPOT responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in Hba1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child worry about casual exposure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in coronary artery calcium (CAC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: paretic pushoff (AGRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond Failure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographic Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in State-Trait Anxiety Inventory (STAI) spouse scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Center for Epidemiologic Studies Depression Scale (CES-D) spouse scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in State-Trait Anxiety Inventory (STAI) patient scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Center for Epidemiologic Studies Depression Scale (CES-D) patient scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tumor Response (Partial or Complete Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prolonged Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weekly mean pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time to Control of Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean log10 HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Esthetic evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to chronic graft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: time to a persistent 25% decrease in Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: time to acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: time to allograft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to select mycophenolate-related toxicities (leukopenia, anemia)
Endpoint domain: Adverse events/effects
Primary endpoint: Total Venous Thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Major or Clinically Relevant Non-major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: level of Blood-Oxygen-Level Dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: level of serotonin transporter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: gained bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median Florescent Intensities (MFI) of the Total Antibodies to Vaccine-included HPV Types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of Persistent HPV 16/18/6/11 Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of HPV 16/18-associated Precancerous Lesions and Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improved insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sleep monitoring
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Caregiver report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sleep diary
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Behavioral monitoring
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Emotional response to exercise induced pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional response to pain-related images
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rates of thrombi formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical significant thrombi or complications
Endpoint domain: Adverse events/effects
Primary endpoint: Complications related to administration of LMWH
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in oral glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accumulative Incidence rate of catheter-related bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of different grades of severity of NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of health anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % body weight ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of cough symptoms total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in metabolic control (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stress urinary incontinence resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hospital readmission for surgical complications
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants With Adherence to Tofacitinib as Assessed by Greater Than or Equal to (>=) 0.8 Proportion of Days Covered (PDC)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fugl-Meyer Upper Limb Motor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes